Background: Niraparib is an oral PARP-1/2 inhibitor with efficacy in both germline BRCA mutated (gBRCA) ovarian cancer (OvCa) and high grade serous OvCa (HGSC) patients ( pts) who are non-gBRCA. Phase I data established a RP2D of 300 mg. At the recommended dose, 75% platinum sensitive patients achieved RECIST response in phase 1. Trial design: ENGOT-OV16/NOVA study (n = 360) is a double-blind, 2:1 randomized, placebo controlled phase III study of oral niraparib versus placebo in pts with platinum ( plat) sensitive recurrent OvCa. Primary objective is to evaluate efficacy of niraparib as maintenance therapy assessed by the prolongation of progression free survival (PFS). PFS will be independently evaluated in a cohort of gBRCA pts and in HGSC pts who are non-gBRCA. Secondary objectives: overall survival in each cohort; bridge the centralized BRCA mutation test method to the candidate companion diagnostic test; patient-reported outcomes; PFS2; chemotherapy free interval; safety/tolerability; QTc in a subset of niraparib-treated pts. Study eligibility includes: histologically confirmed OvCa, HGSC histology or known gBRCA, plat sensitive recurrence, at least 2 prior courses of plat-containing therapy with no/minimal radiological residual disease, and normal CA125 or decrease by 90% after last plat, PS 0-1, and normal organ function.
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